Antibody coupling medicine LZU-WZLY-WYR02 as well as preparation method and application thereof
By conjugating a monoclonal antibody targeting FGFR3 with an enzymatically cleavable linker and cytotoxin, an antibody-drug conjugate (ADC) with a well-defined conjugation ratio and good stability, LZU-WZLY-WYR02 was formed. This solved the problems of low conjugation ratio, poor purity, and unsatisfactory efficacy of existing FGFR3-targeting ADCs, achieving a highly efficient and safe treatment effect for bladder cancer.
Patent Information
- Application Number
- CN202511477254.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-16
- Publication Date
- 2025-12-05
AI Technical Summary
Existing FGFR3-targeted ADC drugs suffer from problems such as low drug conjugation ratio, poor purity, unsatisfactory conjugation method, and insufficient stability and controlled release, resulting in poor efficacy and potential toxic side effects.
A monoclonal antibody targeting fibroblast growth factor receptor 3 (FGFR3) was coupled with the enzymatically cleavable linker Gly-Gly-Phe-Gly (GGFG) and the cytotoxic 7-ethyl-10-fluorocamptothecin (10-FC) via carbonate and amide bonds to form the antibody-drug conjugate LZU-WZLY-WYR02, which has a well-defined drug conjugation ratio and good stability. Optimized synthesis processes ensure its tumor targeting and safety.
It achieves highly efficient tumor targeting and significant anti-tumor activity, reduces toxic side effects, and is superior to traditional chemotherapy regimens and other FGFR3-ADC drugs, demonstrating excellent tumor suppression effect and safety.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the technical field of medicine, and particularly relates to an antibody conjugate drug targeting fibroblast growth factor receptor 3 (FGFR3), a preparation method thereof, and application of the drug in treating FGFR3 high-expression bladder cancer. BACKGROUND
[0002] Bladder cancer is one of the common malignant tumors worldwide, which seriously threatens human health. Among them, non-muscle invasive bladder cancer (NMIBC) accounts for more than 70% of new cases. Although surgery, perfusion chemotherapy and immunotherapy are the main treatment methods at present, NMIBC patients still face a high risk of recurrence, and the existing treatment programs have limited effect on some patients, and there is a large unmet clinical need. Therefore, developing more precise, efficient and safe targeted treatment methods has become a hot spot in bladder cancer research.
[0003] Antibody-drug conjugate (ADC) is an innovative targeted therapeutic drug that ingeniously combines the high targeting of monoclonal antibodies and the strong killing of small molecule toxins. ADC can precisely deliver small molecule drugs into tumor cells, thereby improving the anti-tumor efficacy while significantly reducing the toxic side effects on normal tissues. At present, there are a variety of ADC drugs targeting different targets such as HER2 and TROP2 on the market, which have been approved for cancer treatment and have achieved significant clinical efficacy.
[0004] Fibroblast growth factor receptor 3 (FGFR3) is one of the members of the receptor tyrosine kinase family, which plays an important role in cell proliferation, differentiation, migration and angiogenesis. Studies have shown that FGFR3 is abnormally activated in many tumor types, especially in bladder cancer, with a mutation rate as high as 60%. Overexpression or activating mutations of FGFR3 are closely related to the occurrence, development, invasion and metastasis of tumors, and drug resistance. Compared with other traditional tumor targets, FGFR3 has the characteristics of relatively limited expression range in normal tissues and strong mutation targeting in tumors, making it an ideal target for precise treatment of bladder cancer. Therefore, developing ADC drugs targeting FGFR3 has great clinical potential.
[0005] However, the ADC drugs targeting FGFR3 are still in the clinical research stage. The existing reported FGFR3-ADC schemes mostly use traditional linkers or drug loading molecules, and generally have the following shortcomings: 1) the drug-antibody ratio (DAR) is low, which may affect the efficacy; 2) the connection mode lacks innovation, resulting in poor stability of ADC in blood circulation and controlled release in tumor microenvironment, which may cause side effects or reduce efficacy. Therefore, it is urgent to develop a new FGFR3-targeted ADC drug that can improve the uniformity of ADC drugs, the stability of antibodies, the enzyme-specific cleavage efficiency of linkers, and reduce side effects.
[0006] The present application aims to overcome the defects of the prior art, provide a new antibody conjugate drug LZU-WZLY-WYR02 targeting FGFR3 and an efficient synthesis process thereof, and verify its application potential in FGFR3 high-expression bladder cancer patients, so as to bring new treatment hope for bladder cancer patients. SUMMARY
[0007] The present application aims to overcome the defects of the prior art, provide a new antibody conjugate drug LZU-WZLY-WYR02 targeting FGFR3 and an efficient synthesis process thereof, and verify its application potential in FGFR3 high-expression bladder cancer patients, so as to bring new treatment hope for bladder cancer patients.
[0008] To achieve the above-mentioned purposes, the present application adopts the following technical solutions: An antibody conjugate drug LZU-WZLY-WYR02 comprises a monoclonal antibody targeting fibroblast growth factor receptor 3 (FGFR3), an enzymatically cleavable linker Gly-Gly-Phe-Gly (GGFG), and a cytotoxin 7-ethyl-10-fluorocamptothecin (10-FC); the linker GGFG is connected with 7-ethyl-10-fluorocamptothecin through a carbonate bond, and is coupled to the lysine site of the antibody through an amide bond.
[0009] The antibody is a humanized anti-FGFR3 monoclonal antibody LY3076226 (the original patent is US8043618B2).
[0010] The drug-antibody ratio (DAR) of the antibody conjugate drug is about 6.9-8.0. The chemical structure of the antibody conjugate drug is shown in the following formula (LZU-WZLYCS01): .
[0011] A method for preparing the above antibody conjugate drug, comprising the following steps: (1) Synthesis of linker-toxin conjugate LP-4: under nitrogen protection, intermediate K3 (containing a 7-ethyl-10-F camptothecin skeleton), a GGFG tetrapeptide linker, a condensing agent HATU, and a base DIEA are dissolved in anhydrous DMF, and the reaction is stirred at room temperature for 20-25 hours. After the reaction is completed, extraction, drying, and column chromatography purification are performed to obtain Linker-Payload (LP-4).
[0012] (2) Ultrafiltration: the humanized anti-FGFR3 monoclonal antibody (LY3076226) is subjected to ultrafiltration, 1xPBS (pH 8.0) is used as a buffer, the original buffer system is ensured to be fully replaced, and the protein concentration is determined.
[0013] (3) Antibody reduction treatment: TCEP (10 molar equivalents) and EDTA (final concentration 5 mM) are added to the antibody solution after the replacement, the final protein concentration is adjusted to 1 mg / mL, and after being fully mixed, incubation is performed at 37°C, the disulfide bond of the antibody is selectively reduced by TCEP and EDTA, and the sulfhydryl site is exposed.
[0014] (4) Coupling reaction: DMSO solution of LP-4 is added to the reduced antibody sample, the molar ratio of LP-4 to antibody is controlled to be 15:1, and the coupling reaction is performed at 4°C to improve the specificity and stability of the reaction.
[0015] (5) Reaction termination: after the coupling reaction is completed, N-acetylcysteine (NAC, 10 molar equivalents) is added to quench the unreacted sulfhydryl group and / or excess LP-4, and the coupling reaction is terminated.
[0016] (6) Affinity removal of unconjugated small molecules: affinity chromatography (such as Protein A or Protein G affinity chromatography) is used to purify the reaction mixture to remove unconjugated LP-4, free antibody, and other impurities. The purified antibody conjugate drug is then replaced into a specific storage buffer. The specific buffer is preferably a 100 mM proline, 20 mM arginine, pH 5.0 aqueous solution, which helps to maintain the long-term stability of the ADC. The final product can be stored at -80°C.
[0017] (7) Buffer adjustment and detection: the purified ADC is subjected to buffer adjustment, concentration determination, and quality detection by SEC-HPLC, HIC-HPLC, and ELISA methods to ensure that the purity, DAR value, and binding activity of the product meet the requirements.
[0018] The application of the antibody conjugated drug in the treatment of bladder cancer, including the application in the preparation of drugs for treating bladder cancer with high expression of FGFR3 or FGFR3 mutation. The specific application includes: Activity determination under in vitro conditions: in FGFR3 high expression cell lines such as bladder cancer T24 and UMUC-3, the half inhibitory concentration (IC50) and inhibition curve of the antibody conjugated drug on tumor cells were determined by CCK-8 experiment, the influence of the antibody conjugated drug on the migration ability of tumor cells was evaluated by scratch test and other means, and the killing effect was comprehensively compared with other FGFR3-ADC drugs or chemotherapy regimens, and the antibody conjugated drug had more excellent cytotoxicity.
[0019] In vivo tumor inhibition determination: a nude mouse subcutaneous tumor model (CDX model) and / or a multiple patient-derived tumor xenograft model (PDX model) was constructed using UMUC-3 cells to verify the in vivo antitumor efficacy of the antibody conjugated drug, and the antibody conjugated drug was compared with traditional chemotherapy regimens (such as gemcitabine + cisplatin), FGFR3 monoclonal antibodies or free payloads, and the antibody conjugated drug showed the best tumor inhibition effect and significant inhibition effect on patient tumor tissues.
[0020] Compared with the prior art, the application has the following advantages: 1. Excellent tumor inhibition effect: the ADC (LZU-WZLY-WYR02) designed in the application exhibits strong cytotoxicity on FGFR3 high expression bladder cancer cell lines in in vitro experiments, and the IC50 value reaches the sub-micromolar level; in the cell migration experiment, the ADC can effectively inhibit the migration of tumor cells. In in vivo experiments, whether it is a UMUC-3 cell nude mouse subcutaneous tumor model or a patient-derived PDX tumor model, the ADC shows significant tumor inhibition effect. The tumor inhibition effect is obviously better than that of the commonly used bladder cancer chemotherapy regimen (gemcitabine + cisplatin), is obviously better than the inhibition effect of the FGFR3 monoclonal antibody alone, and is also better than other reported FGFR3-ADC drugs.
[0021] 2. Good safety: compared with the traditional chemotherapy regimen, the ADC drug of the application can effectively inhibit tumor growth without causing obvious body weight loss or other toxic side effects in experimental animals, showing better safety and treatment window.
[0022] 3. High targeting and specificity: due to the use of high-specificity anti-FGFR3 monoclonal antibodies, the ADC of the application can accurately recognize and bind to FGFR3 high expression tumor cells, reducing damage to normal tissues. ELISA experiments prove that the ADC still maintains high binding activity with FGFR3 protein after conjugation.
[0023] 4. Optimized synthesis and purification process: The present application ensures that the prepared FGFR3-ADC drug (LZU-WZLY-WYR02) reaches an advanced level in effectiveness, safety, uniformity and production controllability by precisely controlling key parameters such as TCEP reduction equivalent, molar ratio of LP-4 to antibody, reaction temperature and time. The DAR is as high as 8, and the SEC-HPLC purity can reach more than 99%.
[0024] In summary, the present application provides a new FGFR3 targeted ADC drug LZU-WZLY-WYR02 and its preparation method. Through innovative Linker-Payload design and optimized coupling process, the problems of low coupling ratio, poor purity, poor targeting and efficacy of existing ADC drugs are solved, and the new ADC drug exhibits excellent application prospects in the treatment of bladder cancer, providing a new and more effective treatment option for FGFR3 high expression bladder cancer patients. BRIEF DESCRIPTION OF DRAWINGS
[0025] Figure 1 is the optimization result figure of the coupling conditions of the present application LZU-WZLY-WYR02; Figure 2 is the purity report figure of LZU-WZLY-WYR02; Figure 3 is the endotoxin detection result figure of the FGFR3 monoclonal antibody; Figure 4 is the ELISA binding result figure of the product LZU-WZLY-WYR02 with FGFR3 protein; Figure 5 is the SDS-PAGE electrophoresis figure of LZU-WZLY-WYR02 under reducing and non-reducing conditions; Figure 6 is the IC50 value and inhibition curve figure of LZU-WZLY-WYR02 and other FGFR3-ADCs at the same concentration on bladder cancer T24 and UMUC-3 cells determined by CCK-8; Figure 7 is the influence figure of LZU-WZLY-WYR02 and other FGFR3-ADCs at the same concentration on the migration ability of bladder cancer T24 and UMUC-3 cells determined by cell scratch experiment; Figure 8 is the anti-tumor effect of LZU-WZLY-WYR02 in the nude mouse subcutaneous tumor model constructed by wild type UMUC-3 cells, and the comparison figure with GC scheme, naked antibody, 7-ethyl-10F camptothecin (10-FC) and the mouse weight change figure; Figure 9Figure 1 is a graph of the anti-tumor effect of LZU-WZLY-WYR02 in a PDX model and a graph of the body weight change of mice. DETAILED DESCRIPTION
[0026] The following examples are used to illustrate the present application in detail, but do not limit the scope of the present application. Unless otherwise specified, the reagents used in the present application are analytical pure or above grade, and the water used is deionized water or water of equivalent purity; unless otherwise specified, the buffer involved is based on 1x PBS (pH 7.4). The antibody conjugate drug described in the present application is denoted as LZU-WZLY-WYR02, which is conjugated to the thiol site of the antibody using a cleavable tetrapeptide linker GGFG to form a Linker-Payload (abbreviated as LP-4) with a novel camptothecin derivative 7-ethyl-10-fluorocamptothecin (10-FC). The antibody used is a human IgG1 type anti-FGFR3 monoclonal antibody LY3076226.
[0027] Example 1: Synthesis of LP-4 The present example provides a method for synthesizing the Linker-Payload (LP-4) part of the antibody conjugate drug LZU-WZLY-WYR02.
[0028] (1) Raw material reduction reaction: weigh 4-fluoro-2-aminobenzoic acid (1.0 mmol) and dissolve it in 30 mL of anhydrous tetrahydrofuran (THF), cool it to 0°C in an ice bath, and slowly add LiAlH4(2.0 mmol). After stirring at 0°C for 1 h, continue stirring at room temperature for 18 h. After the reaction, quench with saturated NH4Cl solution, extract, dry the organic layer, and concentrate under reduced pressure to obtain the amino benzyl alcohol compound A2 (yield about 82%).
[0029] (2) Oxidation reaction: dissolve A2 (1.0 mmol) in DCM (20 mL), add MnO2(3.0 mmol), and react at 80°C for 3 h, then naturally cool to room temperature and continue stirring for 1 h. Remove the solid by filtration, and concentrate the filtrate to obtain the amino benzophenone compound B2 (yield about 76%).
[0030] (3) Cyclization to generate quinolinone derivative W2: take B2 (1.0 mmol) and an appropriate amount of cyclization reagent, and reflux in toluene for 12 h under the catalysis of p-toluenesulfonic acid (p-TSA). After cooling, filter, wash, and dry to obtain the quinolinone skeleton compound W2 (yield about 71%).
[0031] (4) Introducing fluorinated camptothecin side chain: W2 (1.0 mmol) was dissolved in a mixed system (FeS04*7H20 2.0 mmol, H2S04 0.1 mL, H20 21 mL, propyl aldehyde 1 mL) and reacted at 0 °C for 45 min. The reaction solution was extracted, dried, and purified to obtain W12 with an ethyl-fluorine-substituted side chain (yield 68%).
[0032] (5) Amino protection to generate J3: W12 was added to Gly-Boc (1.2 eq) in DCM (20 mL) and reacted at room temperature for 24 h under the catalysis of DIPC and DMAP. Purification obtained J3 (yield 80.6%).
[0033] (6) Deprotection to generate K3: J3 was dissolved in DCM (15 mL) and 50% trifluoroacetic acid (TFA) was added, and reacted at room temperature for 24 h. After the solvent was evaporated, K3 was obtained (yield 74.7%).
[0034] (7) Preparation of LP-4 by coupling reaction: K3 (1.0 mmol) was dissolved in anhydrous DMF (10 mL) with MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH (1.1 eq), followed by the addition of HATU (1.2 eq) and DIEA (3 eq) successively, and stirred at room temperature for 24 h. The reaction solution was extracted and purified by column chromatography to obtain LP-4 as a light yellow solid (yield 30.2%). 1H NMR (400 MHz, DMSO) δ 8.59 (t, J = 6.7 Hz, 1H), 8.31-8.22 (m, 3H), 8.19-8.02 (m, 3H), 7.99 (t, J = 5.7 Hz, 1H), 7.78 (td, J = 8.7, 2.8 Hz, 1H), 7.25-7.18 (m, 5H), 7.15 (s, 1H), 6.99 (d, J = 4.7 Hz, 2H), 5.50 (s, 2H), 5.34 (d, J = 3.3 Hz, 2H), 4.59 (d, J = 6.6 Hz, 2H), 4.18 (dd, J = 17.7, 6.1 Hz, 1H), 3.88 (d, J = 15.2 Hz, 2H), 3.66 (d, J = 5.8 Hz, 2H), 3.17 (d, J = 7.7 Hz, 1H), 2.16 (dt, J = 9.4, 6.9 Hz, 2H), 1.47 (q, J = 7.3 Hz, 5H), 1.17 (t, J = 7.1 Hz, 4H), 0.90 (t, J = 7.4 Hz, 3H) MS-ESI m / z: calcd for C 52 H 56 FN9NaO 14 [M + Na] + 1072.3941, found 1072.3930 Example 2: Coupling, purification and structure verification of ADC (1) Antibody pretreatment: humanized anti-FGFR3 monoclonal antibody LY3076226 was selected, and ultrafiltration was performed using 1*PBS (pH 8.0) (the volume of the replacement solution was 8 times the original volume), and the antibody concentration was adjusted to 1 mg / mL. According to the protein amount after replacement, 10 molar equivalents of TCEP (10 mM TCEP solution prepared with 1*PBS, pH 7.4) and EDTA (5 mM) were added to the solution, and incubated at 37°C for 2 h to reduce part of the disulfide bond and expose the thiol reactive site.
[0035] (2) Coupling reaction: In the above reduced antibody solution, DMSO solution (10 mM) of LP-4 was slowly added, and the molar ratio of LP-4 to antibody was controlled at 15:1, and the reaction was carried out at 4°C. After the reaction was completed, 10 molar equivalents of N-acetylcysteine NAC (10 mM NAC solution prepared with 1*PBS, pH 7.4) were added to terminate the reaction and block the unreacted sites to prevent cross-linking.
[0036] (3) Purification and concentration: Protein A affinity chromatography was used to remove uncoupled small molecules, followed by 0.22 μm filter sterilization. The product was further purified by Sephadex G-25 gel filtration, and then replaced into 20 mM arginine / 100 mM proline buffer (pH 5.0) and concentrated for use.
[0037] (4) Quality control HIC-HPLC to determine DAR value: Figure 1 is the optimization result of the coupling conditions of the present application LZU-WZLY-WYR02, which shows that the product is most stable and the DAR is 8 under the preferred 10X TCEP reduction equivalent.
[0038] SEC-HPLC analysis of purity: the purity reached 99.46% ( Figure 2 ).
[0039] ELISA detection of binding activity: the binding curve is basically the same as that of naked LY3076226 (EC 50 ≈ 0.06 μg / mL), indicating that the conjugation does not affect the antigen recognition ability ( Figure 4 ).
[0040] (5) Characterization analysis SDS-PAGE electrophoresis ( Figure 5 ): shows an increase in molecular weight under reducing and non-reducing conditions, which is consistent with the theoretical value of conjugation.
[0041] Example 3: In vivo and in vitro pharmacodynamic verification of ADC in bladder cancer model (1) In vitro cytotoxicity experiment CCK-8 cytotoxicity experiment was performed in FGFR3-positive bladder cancer cell lines T24 and UMUC-3. Cells were inoculated into 96-well plates, treated with different concentrations of LZU-WZLY-WYR02, and the absorbance value was detected after 72 h to calculate the IC 50 . As shown in Figure 6 , the results showed that the IC 50 of T24 cells was 0.007 ± 0.005 μM; the IC 50 of UMUC-3 cells was 0.01 ± 0.001 μM; significantly better than the control drug gemcitabine (0.031 μM and 0.490 μM), and better than other FGFR3-ADC (such as LZU-F001 (antibody conjugate drug prepared with DXD (deruxtecan) as cytotoxicity load), the IC50 of LZU-F001 in T24 and UMUC-3 cell lines for 72 hours was 0.631 μM and 0.855 μM, respectively, and LZU-WZLY-WYR02 had more excellent cytotoxicity.
[0042] (2) Cell migration experiment The effect of LZU-WZLY-WYR02 on bladder cancer cell migration was compared by cell scratch experiment. As shown in Figure 7 , the results showed that after 24 h treatment, the wound healing area of LZU-WZLY-WYR02 group was significantly slowed down, and the cell migration area was lower than that of other FGFR3-ADC (LZU-F001) group, indicating that the ADC could significantly inhibit the migration ability of tumor cells.
[0043] (3) Verification of target binding activity The LAL method was used to detect the endotoxin content of FGFR3 monoclonal antibody, which was 0.33 EU / mg, lower than the standard limit (<1 EU / mg), indicating that the antibody had high purity and the bacterial endotoxin level met the requirements, and could be used for subsequent in vitro binding activity and in vivo efficacy experiments. Figure 3 ).
[0044] ELISA was used to detect the binding ability of LZU-WZLY-WYR02 and FGFR3 recombinant protein, and the EC 50 was approximately 0.06 μg / mL, and the curve overlapped with the naked antibody, indicating that the conjugation process did not affect the antigen affinity. Figure 4 ).
[0045] (4) In vivo pharmacodynamics study (CDX model) UMUC-3 cells (1×10 7(cells / mL) were subcutaneously injected into BALB / c nude mice. When the tumor volume reached approximately 100 mm³, the mice were randomly assigned to the following groups: saline control group; FGFR3 monoclonal antibody group (5 mg / kg); gemcitabine 20 mg / kg + cisplatin 2 mg / kg group; LZU-WZLY-WYR02 group (5 mg / kg, once a week for 2 weeks); LZU-WZLY-WYR02 group (10 mg / kg, once a week for 2 weeks). Body weight and tumor volume were measured every 3 days during treatment. Results showed that LZU-WZLY-WYR02 significantly inhibited tumor growth (cells / mL). Figure 8 A, Figure 8 B), and there was no significant weight loss or adverse reactions (B). Figure 8 C).
[0046] (5) PDX model validation Tumor tissues were obtained from bladder cancer patients with high FGFR3 expression to construct a three-stage passage (G3) PDX model. When the tumor volume reached 50–100 mm³, patients were divided into three groups for drug administration: saline control group; 10F-FC 0.1 mg / kg group; LZU-WZLY-WYR02 5 mg / kg group; and LZU-WZLY-WYR02 10 mg / kg group. The drugs were administered via tail vein injection (once a week for a total of 2 weeks). Results showed that tumor growth was significantly inhibited in the LZU-WZLY-WYR02 treatment group (…). Figure 9 A, Figure 9 B), mouse weight stabilized ( Figure 9 C).
[0047] In summary, the antibody-drug conjugate of this invention consists of three parts: first, a humanized monoclonal antibody targeting fibroblast growth factor receptor 3 (FGFR3) for specific recognition of tumor cells; second, a linker peptide containing the Gly-Gly-Phe-Gly (GGFG) sequence, serving as an enzymatically cleavable linker to ensure drug stability in vivo and effective release within the tumor; and third, a camptothecin derivative, 7-ethyl-10-fluorocamptothecin, serving as the drug-loading component with significant cytotoxic effects. This ternary structure conjugates the linker to the antibody via specific lysine residues and forms carbonate bonds with the toxin, resulting in a well-defined, DAR-uniform, and stable ADC drug. LZU-WZLY-WYR02 exhibits sub-micromolar inhibitory activity in vitro and significantly inhibits tumor growth in vivo with excellent safety. Compared to the chemotherapy drug gemcitabine and other FGFR3-ADCs, it demonstrates stronger efficacy, lower toxicity, and better targeting, providing a new candidate drug for precision treatment of bladder cancer.
[0048] The above examples are only for illustrating the technical concept and characteristics of the present application, and the purpose is to enable those skilled in the art to understand the content of the present application and to implement it, and cannot limit the protection scope of the present application. Any equivalent changes or modifications made according to the spirit and essence of the present application shall be covered within the protection scope of the present application.
Claims
1. An antibody drug conjugate LZU-WZLY-WYR02, characterized in that, The antibody conjugate drug comprises a monoclonal antibody targeting fibroblast growth factor receptor 3 (FGFR3), a cleavable linker GGFG and a cytotoxin 7-ethyl-10-fluoro camptothecin; the linker GGFG is connected with 7-ethyl-10-fluoro camptothecin through a carbonate bond and is coupled to a lysine site of the antibody through an amide bond.
2. The antibody-drug conjugate LZU-WZLY-WYR02 as described in claim 1, characterized in that: The monoclonal antibody is humanized antibody LY3076226.
3. The antibody-drug conjugate LZU-WZLY-WYR02 as described in claim 1, characterized in that: The drug coupling ratio (DAR) of the antibody conjugate drug is 6.9-8.0; and the structural formula of the antibody conjugate drug is: 。 4. A method for preparing the antibody conjugate drug LZU-WZLY-WYR02 according to any one of claims 1-3, characterized in that, The method comprises the following steps: (1) Synthesis of linker-toxin conjugate LP-4: intermediate K3 containing 7-ethyl-10-fluoro camptothecin is coupled with linker GGFG through amide condensation reaction to obtain LP-4; 7-ethyl-10-fluoro camptothecin has the structural formula ; and intermediate K3 has the structural formula ; (2) Antibody reduction treatment: humanized anti-FGFR3 monoclonal antibody is treated with reducing agent TCEP and EDTA to selectively reduce its disulfide bond and expose the thiol site; (3) Coupling reaction: LP-4 obtained in step (1) is coupled with the reduced antibody in step (2); (4) Reaction termination and purification: N-acetylcysteine is added to terminate the coupling reaction, and the target antibody conjugate drug LZU-WZLY-WYR02 is obtained by chromatography purification and is replaced into a specific buffer for storage.
5. The method of claim 4, wherein, In step (1), the preparation method of LP-4 comprises the following steps: i) 7-ethyl-10-fluoro camptothecin, N-Boc glycine, condensing agent EDCI and catalyst DMAP are dissolved in dichloromethane, and stirred at room temperature for 20-25 h; after the reaction is completed, the crude product is obtained by extraction, washing, drying and concentration, and then the Boc protecting group is removed, and the intermediate compound K3 is obtained by purification; ii) Compound K3 is dissolved in DMF with linker GGFG, condensing agent HATU and organic base DIEA, and stirred under nitrogen protection for 20-25 h; after the reaction is completed, the target product LP-4 is obtained by extraction, washing, drying, concentration and purification; The structural formula of LP-4 is: 。 6. The preparation method according to claim 5, characterized in that, In step i), the molar ratio of 7-ethyl-10-fluoro camptothecin, N-Boc glycine, condensing agent EDCI and catalyst DMAP is 1: (2.0-2.5): (1.0-1.5): (1.5-2.0); in step ii), the molar ratio of compound K3 and GGFG linker is 1:
1.
7. The method of claim 4, wherein, In step (2), the amount of reducing agent TCEP is 10 molar equivalents of the antibody, the concentration of EDTA is 5 mM, and the final concentration of the antibody is 1 mg / mL, and the incubation is carried out at 37°C for 2 hours; in step (3), the molar ratio of LP-4 to the reduced antibody is 15:1, and the coupling reaction is carried out at 4°C; in step (4), the molar equivalent ratio of N-acetylcysteine to LP-4 is 10:1; and the specific buffer is a solution containing 100 mM proline, 20 mM arginine and pH=5.
0.
8. Use of the antibody conjugate drug of any one of claims 1-3 in the preparation of a drug for treating bladder cancer.
9. Use according to claim 8, characterized in that, The bladder cancer is FGFR3 high expression or FGFR3 mutation bladder cancer.
10. Use according to claim 9, characterized in that, The bladder cancer is FGFR3 positive non-muscle invasive bladder cancer, and the administration mode is intravenous injection.
Citation Information
Patent Citations
Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
US8043618B2
